Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Puma Biotechnology (NQ: PBYI )

2.555 +0.055 (+2.20%)
Streaming Delayed Price Updated: 3:33 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Puma Biotechnology

< Previous 1 2 3 4 Next >
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Second Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Join Russell 3000 Index
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports First Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
3 small-cap biotechs with potential breakthroughs in 2024
These small-cap biotech stocks feature large addressable markets combined with positive analyst sentiment and potential breakthroughs in 2024. 
Via MarketBeat
Topics Bankruptcy
Exposures Financial Legal
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Third Quarter 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.